IL132770A0 - Caspases and apoptosis - Google Patents

Caspases and apoptosis

Info

Publication number
IL132770A0
IL132770A0 IL13277098A IL13277098A IL132770A0 IL 132770 A0 IL132770 A0 IL 132770A0 IL 13277098 A IL13277098 A IL 13277098A IL 13277098 A IL13277098 A IL 13277098A IL 132770 A0 IL132770 A0 IL 132770A0
Authority
IL
Israel
Prior art keywords
caspases
apoptosis
Prior art date
Application number
IL13277098A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL132770A0 publication Critical patent/IL132770A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IL13277098A 1997-07-30 1998-07-30 Caspases and apoptosis IL132770A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5425597P 1997-07-30 1997-07-30
PCT/US1998/015935 WO1999006367A1 (en) 1997-07-30 1998-07-30 Caspases and apoptosis

Publications (1)

Publication Number Publication Date
IL132770A0 true IL132770A0 (en) 2001-03-19

Family

ID=21989796

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13277098A IL132770A0 (en) 1997-07-30 1998-07-30 Caspases and apoptosis

Country Status (10)

Country Link
US (1) US6403792B1 (es)
EP (1) EP1001933A4 (es)
JP (1) JP2001512100A (es)
AR (1) AR016384A1 (es)
AU (1) AU8763298A (es)
CA (1) CA2297757A1 (es)
CO (1) CO4970752A1 (es)
IL (1) IL132770A0 (es)
WO (1) WO1999006367A1 (es)
ZA (1) ZA986760B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR016551A1 (es) * 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
WO2000009480A1 (fr) * 1998-08-11 2000-02-24 Daiichi Pharmaceutical Co., Ltd. Nouveaux derives sulfonyle
AU7625500A (en) * 1999-09-30 2001-04-30 Smithkline Beecham Corporation Caspases and apoptosis
WO2001045716A1 (en) * 1999-12-20 2001-06-28 Gho'st Holding B.V. Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and a na+/h+ exchange inhibitor
AU2001262711A1 (en) * 2000-06-08 2001-12-17 Mitsubishi Pharma Corporation Cytoprotectors
SE0004780D0 (sv) 2000-12-22 2000-12-22 Jordanian Pharmaceutical Mfg & Novel compunds
AT413485B (de) * 2001-04-09 2006-03-15 Hemoteq Gmbh Mit einem pharmazeutikum beschichteter stent
AU2003224482A1 (en) 2002-04-30 2003-11-17 Korea Research Institute Of Chemical Technology Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
GB0327494D0 (en) * 2003-11-26 2003-12-31 Amersham Plc Novel imaging agents
US7256198B2 (en) 2004-02-18 2007-08-14 Wyeth Pyrimidoindolones and methods for using same
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US8586571B2 (en) * 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN102171208A (zh) 2008-09-05 2011-08-31 帝国创新有限公司 用作体内显像剂的靛红衍生物
EP3309151A1 (en) * 2009-06-25 2018-04-18 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
AU2011245441B2 (en) 2010-04-29 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
CA2850707C (en) 2011-10-03 2023-03-21 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
CN103183631B (zh) * 2011-12-28 2016-08-24 天津市国际生物医药联合研究院 靛红-5-磺酰胺类衍生物及其在制备治疗非典型性肺炎的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE715760C (de) * 1938-12-02 1942-01-07 Ig Farbenindustrie Ag Verfahren zur Herstellung von Sulfonamiden der Indolreihe
MC1357A1 (fr) 1979-12-07 1981-08-10 Hoffmann La Roche Derives de 2,3-indoledione
SE434638B (sv) * 1980-06-06 1984-08-06 Lekemedelsfabriken Medica Ab Nya terapeutiska verdefulla taurinderivat och deras framstellning
US5164404A (en) * 1991-03-15 1992-11-17 Neurosearch A/S Hydrazone derivatives and their use
AU655643B2 (en) * 1991-07-09 1995-01-05 Neurosearch A/S Novel isatineoxime derivatives, their preparation and use
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use

Also Published As

Publication number Publication date
ZA986760B (en) 1999-02-01
JP2001512100A (ja) 2001-08-21
US6403792B1 (en) 2002-06-11
EP1001933A1 (en) 2000-05-24
AU8763298A (en) 1999-02-22
EP1001933A4 (en) 2002-11-06
AR016384A1 (es) 2001-07-04
CO4970752A1 (es) 2000-11-07
WO1999006367A1 (en) 1999-02-11
CA2297757A1 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
EP1021185A4 (en) DIHYDROPYRIMIDINE AND ITS USES.
IL132770A0 (en) Caspases and apoptosis
IL126383A0 (en) Apo-2li and apo-3 apoptosis polypeptides
ZA986761B (en) Caspases and apoptosis
HUP9700446A3 (en) Oilsuspension-concentrate and using thereof
GB9704776D0 (en) Detergent - packaging combination
EP1087663A4 (en) CASPASES AND APOPTOSIS
GB9803066D0 (en) Lamp unit and arrangement
EP1242081A4 (en) CASPASES AND APOPTOSIS
PL331523A1 (en) Azolotrizines and azolopyrimidines
EP1129108A4 (en) CASPASES AND APOPTOSIS
EP0998578A4 (en) SEL-10 AND USES OF SEL-10
EP1146337A4 (en) PGT AND APOPTOSE
HUP9900068A3 (en) Fuse-switch and/or fuse-disconnector
PL341293A1 (en) Beta-lypothropin and application thereof
GB2322310B (en) Shredder
ZA987425B (en) Phenylethanolaminotetralin derivatives and bronchodilators
GB9720258D0 (en) Extravise and Inavise
IL134499A0 (en) Pyrimidin-2- oxy-4-one and pyrimidin-2-oxy- 4-thione derivatives
GB9708155D0 (en) Add and see
GB9802016D0 (en) Bootsac and coolsac
AU1251P (en) LEMON COLOURBURST Bracteantha bracteata
GB9609498D0 (en) Aqua-saucer and aqua-vase
SG71798A1 (en) Switch assembly and switch arrangement